TmPSMA-02 CAR T Cells

Phase 1Cell therapy

TmPSMA-02 CAR T Cells is one of 2 small molecule programs targeting Castrate Resistant Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castrate Resistant Prostate CancerActive, not recruiting

Castrate Resistant Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Castrate Resistant Prostate Cancer

#DrugCompanyPhaseTrials

TmPSMA-02 CAR T Cells

UUniversity of Pennsylvania

Phase 1

1 2

JSB462

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2042

Phase 1Active, not recruiting

Castrate Resistant Prostate Cancer

NCT06046040

Clinical

Trials by Indication[1]

Castrate Resistant Prostate Cancer1 trial

Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT06046040·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TmPSMA-02 CAR T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TmPSMA-02 CAR T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TmPSMA-02 CAR T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

TmPSMA-02 CAR T Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2042

Trials by Indication[1]

Castrate Resistant Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News